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Methods for the targeted disruption of protein func-
tion have revolutionized science and greatly expe-
dited the systematic characterization of genes. Two
main approaches are currently used to disrupt pro-
tein function: DNA knockout and RNA interference,
which act at the genome and mRNA level, respec-
tively. A method that directly alters endogenous
protein levels is currently not available. Here, we pre-
sent Trim-Away, a technique to degrade endogenous
proteins acutely in mammalian cells without prior
modification of the genome or mRNA. Trim-Away
harnesses the cellular protein degradation machin-
ery to remove unmodified native proteins within
minutes of application. This rapidity minimizes the
risk that phenotypes are compensated and that
secondary, non-specific defects accumulate over
time. Because Trim-Away utilizes antibodies, it can
be applied to a wide range of target proteins using
off-the-shelf reagents. Trim-Away allows the study
of protein function in diverse cell types, including
non-dividing primary cells where genome- and
RNA-targeting methods are limited.
INTRODUCTION
Interfering with protein expression is a powerful strategy to
investigate the function of a protein. Traditionally, DNA-modi-
fying methods have been used to knockout proteins on the
gene level (Capecchi, 1989), an approach that has had a recent
resurgence with the emergence of CRISPR/Cas9 technology
(Doudna and Charpentier, 2014). RNA-targeting methods such
as RNAi are also widely used to knockdown expression of a pro-
tein by destroying the mRNA (Elbashir et al., 2001). However, in
both approaches, protein depletion is indirect and dependent on
the inherent turnover of the protein. Consequently, long-lived
proteins take more time to deplete, or may be resistant to
DNA- and RNA-targeting depletion methods altogether (Jansen
et al., 2007; Smoak et al., 2016). The long time frame that is
required for protein depletion with these methods also means
that cells may have enough time to activate compensatory1692 Cell 172, 1692–1706, December 14, 2017 ª 2017 The Authors.
This is an open access article under the CC BY license (http://creativemechanisms, which may mask phenotypes (Damke et al.,
1995; Rossi et al., 2015). Furthermore, it is often impossible to
determine whether or not a phenotype is an indirect conse-
quence of an earlier defect. In an attempt to overcome these
problems, several methods have been developed for conditional
protein inactivation. However, these methods require that either
the protein of interest is first modified (Banaszynski et al., 2006;
Caussinus et al., 2011; Neklesa et al., 2011; Nishimura et al.,
2009; Robinson et al., 2010; Tachibana-Konwalski et al., 2010)
or can only be applied to a very small number of proteins (De-
shaies, 2015; Fan et al., 2014). Chemical inhibitors can be equally
problematic as they are limited to druggable proteins and prone
to off-target effects (Mayer, 2003). A widely applicable protein
depletion method that acts exclusively at the protein level is
currently lacking. Such a method would not only allow the acute
depletion of endogenous proteins, but also the study of protein
function in non-dividing primary cells in which DNA-targeting
must be done at the whole animal level and RNA-targeting
cannot deplete stable proteins.
We sought to develop a truly posttranslational protein deple-
tion method based on protein targeting by antibodies. Anti-
bodies bind to proteins with high affinity and specificity; they
are widely available commercially and can be produced for
almost any protein with relative ease. Antibodies are therefore
ideal as the basis of a protein-targeting method. Antibodies
have been used previously to interfere with protein function
(Morgan and Roth, 1988). However, this requires that the anti-
body binds to an epitope that blocks the function of a protein
and can effectively and stoichiometrically compete with endog-
enous ligands. This method of inhibition is therefore only appli-
cable to a very limited number of proteins. Instead, we aimed
to develop a universally applicable method that would allow us
to target any antibody-bound protein for degradation.
Antibody-bound pathogens can be recognized by the cyto-
solic antibody receptor, TRIM21 (Mallery et al., 2010). TRIM21
is an E3 ubiquitin ligase that binds with high affinity to the Fc
domain of antibodies (James et al., 2007). TRIM21 is widely ex-
pressed in diverse cell types and tissues, which is a necessary
requirement of its physiological role (Yoshimi et al., 2009). Dur-
ing infection, TRIM21 recruits the ubiquitin-proteasome system
to antibody-bound pathogens, leading to their destruction (Mal-
lery et al., 2010). TRIM21 causes degradation of diverse patho-
gens including RNA and DNA viruses (Watkinson et al., 2015),
bacteria (McEwan et al., 2013), and the proteopathic agentPublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. Acute Degradation of Proteins by
Trim-Away
(A) Schematic of Trim-Away approach.
(B–E) NIH 3T3 cells overexpressing mCherry-
TRIM21 (not shown) and free GFP (greys) were mi-
croinjected with anti-GFP antibody or control IgG
(B and C) or treated with DMSO or MG132 and mi-
croinjected with anti-GFP antibody (D and E). Time
shows minutes (min) from antibody microinjection;
0 min is just before antibody microinjection. Dashed
line outlines cell. Scale bars, 10 mm. Error bars show
SD. Number of cells is specified in brackets. Data
from three (C and E) independent experiments.
See also Figures S1 and S3–S7 and Movie S1.Tau (McEwan et al., 2017). Both the proteasome and the AAA
ATPase VCP/p97 have been identified as important co-factors
for degradation, but their requirement differs between sub-
strates (Hauler et al., 2012).
The E2 enzymes Ube2W and Ube2N/2V2 have also been
implicated in TRIM21-mediated degradation (Fletcher et al.,
2015). These enzymes act sequentially on TRIM21 itself, first
mono-ubiquitinating it (Ube2W) and then extending from this a
K63-ubiquitin chain (Ube2N/2V2). TRIM21 is also modified with
K48-chains but the E2 enzyme(s) involved are unknown, as is
the functional importance of this modification. TRIM21 has not
been reported to modify the pathogen or the pathogen bound
antibodies, but it is unclear if such modifications have escaped
detection or if auto-ubiquitination of TRIM21 is sufficient for
pathogen destruction. TRIM21 has also been reported to interact
with several other proteins including Skp2, DAXX, IRF-3, IRF-5,
IRF-8, DDX41, and SQSTM1 (James, 2014). However, most of
these interactions have been detected based on immunoprecip-
itation, which can deliver false positives because of direct bind-
ing of TRIM21 to the antibodies used in the assay.
In this study, we repurposed TRIM21 to establish a method to
degrade endogenous proteins that we called Trim-Away. Trim-
Away allows the study of protein function in various cell types,
including non-dividing primary cells where genome- and RNA-
targeting methods are not well suited. Trim-Away degrades pro-
teins within minutes of application, making it suitable to investi-
gate the function of a protein long after it has formed and at
all stages of a cell’s life, cycle, or differentiation. Acute protein
disruption assays, which in the past have required complexCegenetics and a lot of time, can now be
done by Trim-Away within hours. Trim-
Away therefore forms the basis for the sys-
tematic stage-specific analysis of protein
function.
RESULTS
Principle of Protein Degradation by
Trim-Away
We reasoned that the antibody receptor
and ubiquitin ligase TRIM21 could be used
as a tool to drive the degradation of endog-
enous proteins by using a 3-step strategy:first, the introduction of exogenous TRIM21; second, the intro-
duction of an antibody against the protein of interest; and third,
TRIM21-mediated ubiquitination followed by degradation of the
antibody-bound protein of interest (Figure 1A). As we outline in
detail below, this strategy, which we called ‘‘Trim-Away,’’ is
ideally suited for the acute and rapid degradation of endogenous
proteins in both individual cells as well as bulk cell populations.
To test the Trim-Away strategy, we first set up a proof of prin-
ciple experiment in mammalian cell culture. NIH 3T3 cells over-
expressing mCherry-TRIM21 and free GFP were microinjected
with anti-GFP antibody (Figure 1B). Remarkably, GFP was
rapidly degraded following microinjection with a half-life of just
16 min (Figures 1B, 1C, and S3A; Movie S1). mCherry-TRIM21
colocalized with GFP during degradation, consistent with
TRIM21 recruitment to GFP via the anti-GFP antibody (Figures
S1A and S1B; Movie S1). GFP aggregated quickly at the site of
antibody microinjection, likely because of the high local concen-
tration of anti-GFP antibody (Figures 1B and S1A). Degradation
was specifically due to targeting of GFP by anti-GFP antibody,
because microinjection of a non-specific control IgG did not
cause GFP degradation in mCherry-TRIM21-overexpressing
cells (Figures 1B, 1C, and S1A–S1D). The degradation of GFP
was dependent on TRIM21 overexpression, because anti-GFP
antibody failed to trigger GFP degradation in cells that overex-
pressed mCherry instead of mCherry-TRIM21 (Figures S1E
and S1F). The E3 ubiquitin ligase activity of TRIM21was required
for degradation, because a truncated form of TRIM21 lacking
the RING E3 ubiquitin ligase and B-Box domains (mCherry-
TRIM21DRING-Box) efficiently colocalized with GFP followingll 172, 1692–1706, December 14, 2017 1693
anti-GFP antibodymicroinjection, but failed to causeGFPdegra-
dation (Figures S1G and S1H).
To test if protein degradation by Trim-Away is mediated by
the proteasome consistent with the known mechanism of
TRIM21 function, we treated cells with the proteasome inhibitor
MG132. Strikingly, MG132 treatment prevented the degradation
of GFP following anti-GFP antibodymicroinjection into mCherry-
TRIM21-overexpressing cells (Figures 1D and 1E). Therefore,
protein degradation by Trim-Away relies on the ubiquitin-protea-
some pathway (Figure 1A).
Trim-Away Can Be Used to Degrade Proteins in
Primary Cells
We next asked if Trim-Away could be applied to post-mitotic
primary cells. We chose mammalian oocytes because they are
transcriptionally silent, which precludes protein disruption by
direct genome editing. Moreover, RNAi is inefficient in these cells
due to large amounts of stored proteins (Clift and Schuh, 2013;
Pfender et al., 2015). We first tested if TRIM21 overexpression
has any influence on oocyte meiosis. Oocytes that overex-
pressed TRIM21 progressed through meiosis with similar effi-
ciency and timing as control oocytes: neither the rate nor the
timing of nuclear envelope breakdown or anaphase was signifi-
cantly different (Figures S6A–S6C, S6E, and S6F). Also spindle
morphology during meiosis I and meiosis II was not perturbed
(Figures S6A, S6D, and S6G). Thus, TRIM21 overexpression
does not perturb oocyte meiosis.
We then performed a similar proof-of-principle GFP degrada-
tion experiment as described above in isolated mouse oocytes.
Microinjected anti-GFP antibody triggered rapid GFP degrada-
tion in oocytes overexpressing mCherry-TRIM21. In contrast,
control IgG had no effect on GFP protein levels (Figures 2A
and 2B). As in NIH 3T3 cells, mCherry-TRIM21 colocalized with
GFP during GFP degradation (Figure S2A), andGFP degradation
was dependent on TRIM21’s ubiquitin ligase activity (Figures
S2C–S2H). Before protein degradation, we observed a transient
increase in GFP intensity at the site of GFP-antibody microinjec-
tion (Figure 2A). This is likely due to a local enrichment of GFP-
antibody at themicroinjection site, which results in sequestration
of GFP from the entire oocyte volume to this region.
We noticed that mCherry-TRIM21 was depleted concomi-
tantly with GFP upon anti-GFP antibody microinjection (Figures
S2A and S2B). Western blotting of whole cell extracts confirmed
that TRIM21, antibody and target protein are all degraded during
Trim-Away (Figure S2I). This is consistent with the proposed
mechanism of TRIM21 function and suggests that TRIM21 and
antibody levels could become limiting during Trim-Away if the
target is in significant molar excess. To investigate this further,
we modified relative levels of TRIM21 and GFP and found that
TRIM21 needs to be present in excess of the target protein to
facilitate complete protein degradation (Figures S2J–S2L).
Trim-Away Can Target Diverse Cellular Substrates
A widely applicable protein depletion method should be able to
target diverse substrateswithin the cell. To address this, we local-
izedGFP to different regionsof thecell and tested the efficiencyof
degradation by Trim-Away. GFP containing anN-terminal N-myr-
istoyl and S-palmitoyl motif (membrane-anchored GFP) localized1694 Cell 172, 1692–1706, December 14, 2017to the plasma membrane and vesicle-like structures in the cyto-
plasm (Figure 2C); GFP fused to the histone H2B (H2B-GFP)
was efficiently incorporated into chromatin (Figure 2E); GFP con-
taining a nuclear localization signal (NLS-GFP) accumulated in the
nucleus (Figure 2G). All three different substrates were rapidly
degraded by anti-GFP antibody and TRIM21 with similar kinetics
to free cytosolic GFP (Figures 2C–2H). Remarkably, the half-life
for degradation by Trim-Away was as little as 9 min (Figures 2B,
2D, 2F, 2H and S3A). This is identical to the rate of protein degra-
dation achieved by the auxin-inducible degron system (Holland
et al., 2012), but with the advantage that Trim-Away requires no
modification of the target protein. Altogether, these data show
thatTrim-Awaycandegradeproteins that are localized todifferent
regions of the cell and incorporated into larger protein complexes
and cellular structures.
We noticed that NLS-GFP was degraded in the cytoplasm,
presumably because NLS-GFP shuttles in and out of the nucleus
and can therefore be bound by antibodies in the cytoplasm (Fig-
ure 2G). We therefore tested if Trim-Away can also degrade re-
tained nuclear proteins, such as GFP-H2B that is stably associ-
ated with chromatin within the nucleus. In contrast to NLS-GFP,
GFP-H2B was not degraded when the chromatin was contained
within an intact nucleus (Figures S3B and S3C). We reasoned
that we might be able to overcome this limitation by fusing
the Fc-domain of an antibody to a nanobody. The Fc-nanobody
fusion is much smaller in size and should be able to enter the
nucleus. Strikingly, H2B-GFP was quickly degraded also inside
the nucleus when TRIM21 and the Fc-nanobody fusion were
co-expressed (Figures 2I–2K). This demonstrates that Fc-nano-
body fusions can be used to degrade proteins inside the nucleus.
It also illustrates that the growing number of nanobodies is
compatible with Trim-Away when these nanobodies are fused
with an Fc-domain.
Rescue Experiments Confirm Trim-Away Specificity
In principle, it should be possible to degrade any endogenous
protein in the cell that can be accessed by antibodies using
Trim-Away (Figure 1A). To test this, we decided to target an
endogenous protein in mouse oocytes called Eg5. Eg5 is a
microtubule motor protein required for proper spindle assembly
during mitosis and meiosis (Clift and Schuh, 2015; Mayer et al.,
1999; Schuh and Ellenberg, 2007). When the function of Eg5 is
disrupted, a monopolar microtubule aster forms and the spindle
fails to become bipolar. We chose to Trim-Away Eg5 becausewe
could directly compare the phenotype following Eg5 degrada-
tion to that of Eg5 inhibition with the small molecule inhibitor
monastrol (Mayer et al., 1999).
Strikingly, microinjection of anti-Eg5 antibody into oocytes
overexpressing TRIM21 caused the formation of monopolar
spindles; precisely the phenotype expected if Eg5 is degraded
and identical to oocytes treated with the Eg5 inhibitor monastrol
(Figures 3A–3C). Neither control IgGmicroinjection into TRIM21-
overexpressing oocytes, nor anti-Eg5 antibody microinjection
alone caused monopolar spindles (Figures 3B and 3C), con-
firming that Eg5 degradation requires both TRIM21 and anti-
Eg5 antibody. Eg5 protein was completely degraded as
shown by immunoblotting with two different anti-Eg5 antibodies
(Figure 3D).
(legend on next page)
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To confirm that the monopolar spindle phenotype was due to
Eg5 degradation, we performed a rescue experiment by micro-
injecting mRNA encoding Eg5-mEGFP into Eg5 Trim-Away oo-
cytes (Figures 3A and 3E). Eg5-mEGFP expression transformed
the monopolar spindles back to a bipolar state (Figures 3E
and 3F; Movie S2). Eg5-mEGFP can be recognized by anti-Eg5
antibody, but likely rescues because it is expressed in excess.
Altogether, these data show that endogenous proteins can be
degraded using Trim-Away, and rescue assays can be used to
confirm the specificity of a Trim-Away phenotype.
Trim-Away Is Suitable to Degrade Long-Lived Proteins
Acutely
Long-lived intracellular proteins are surprisingly common
(Toyama et al., 2013), but studying their function is challenging.
The lack of protein turnover means that depletion by RNAi is inef-
fective.Geneknockoutsarealsooftennot suitable, because long-
lived proteins are frequently especially important in non-dividing
primary cells and essential for viability (Toyama et al., 2013). We
reasoned that because Trim-Away acts exclusively at the protein
level, it should be suitable to degrade even very long-lived pro-
teins and thereby study their function long after their synthesis.
To test this, we targeted the long-lived Rec8 protein in mouse
eggs that were arrested in metaphase of the second meiotic di-
vision. Rec8 is part of the cohesin protein complex that mediates
sister chromatid cohesion in oocytes from birth until ovulation
(Tachibana-Konwalski et al., 2010). Rec8 does not turnover
(Tachibana-Konwalski et al., 2010), but remains stably associ-
ated with chromosomes for months in mice and possibly de-
cades in humans.
We asked if we could use Trim-Away to degrade endogenous
Rec8 acutely in metaphase II arrested eggs, long after it has
been incorporated into chromosomes. Microinjection of anti-
Rec8 antibody (Eijpe et al., 2003) into eggs overexpressing
mEGFP-TRIM21 triggered the premature separation of sister
chromatids (Figures 4A–4C; Movie S3), producing 40 single
chromatids (Figure 4D), which is indicative of Rec8 degradation
and complete loss of sister chromatid cohesion (Tachibana-
Konwalski et al., 2010). No separation was observed when con-
trol IgG was microinjected into mEGFP-TRIM21-overexpressing
oocytes or when oocytes overexpressing antibody-binding-defi-
cient TRIM21 (mEGFP-TRIM21DPRYSPRY) were microinjected
with anti-Rec8 antibody (Figures 4B and 4C). This confirmed
that sister chromatid separation was due to Rec8 degradation
triggered by TRIM21 recruitment to Rec8 via anti-Rec8 antibody
(Figure 4A). Previous functional studies of Rec8 required com-
plex mouse genetics to replace the Rec8 gene with a versionFigure 2. Trim-Away Degrades Diverse Cellular Substrates
(A–H) Oocytes overexpressingmCherry-TRIM21 (not shown) and either free GFP (
(G and H) were microinjected with either anti-GFP antibody or control IgG. Time s
microinjection.
(I) Schematic of nanobody-Fc fusion approach.
(J and K) Prophase-arrested oocytes expressing H2B-GFP were microinjected w
GFP nanobody-Fc fusion protein. (J) Representative examples and (K) quantifica
White dashed line outlines oocyte. Yellow arrow shows H2B-GFP. Yellow dash
oocytes is specified in brackets. Data from three (B) or two (D, F, H, and K) inde
See also Figures S2–S7.
1696 Cell 172, 1692–1706, December 14, 2017that expresses a TEV protease-cleavable Rec8 protein (Tachi-
bana-Konwalski et al., 2010). The Rec8 Trim-Away experiments
described here provide the first evidence that endogenous,
unmodified Rec8 protein is responsible for sister chromatid
cohesion in mouse eggs. Remarkably, sister chromatids began
to separate on average just 11 min after anti-Rec8 antibody
microinjection into mEGFP-TRIM21-overexpressing eggs (Fig-
ures 4B and 4E), implying Trim-Away can degrade even very
long-lived proteins with unprecedented speed.
Trim-Away Can Be Used to Degrade Specific Protein
Variants Selectively
Given that Trim-Away capitalizes on the high specificity of anti-
bodies, it should also be suitable to selectively degrade splice
variants, posttranslationally modified or disease-causing protein
variants while preserving the healthy protein, as long as anti-
bodies are available that are variant-specific. To test this, we
asked if Trim-Away can be used to selectively degrade
the disease-causing variant of the protein huntingtin, which
causes Huntington’s disease. We co-expressed the normal or
the disease-causing variant of huntingtin protein together with
mCherry-TRIM21 in NIH 3T3 cells. We then microinjected the
cells with an antibody (3B5H10) which specifically binds to the
disease-causing variant of huntingtin (Miller et al., 2011) (Fig-
ure S4A). The disease-causing variant of huntingtin protein was
rapidly degraded following microinjection of the antibody,
whereas normal huntingtin protein was preserved (Figures S4A
and S4B). Similar results were obtained in oocytes that
expressed both the normal and the disease-causing variant
of huntingtin simultaneously: the disease-causing variant was
degraded, while the normal variant was preserved (Figures
S4C and S4D). This demonstrates that Trim-Away can be used
to degrade specific protein variants selectively.
Antibody Electroporation Allows Trim-Away in Bulk Cell
Populations
While microinjection is suitable for studying individual cells, most
assays require the manipulation of bulk cell populations. We
therefore aimed to develop a method of antibody and TRIM21
delivery that wouldmake Trim-Away applicable to large numbers
of cells simultaneously. Recent work has shown that antibodies
can be delivered into the cytoplasm by electroporation (Freund
et al., 2013), suggesting that antibody electroporation could be
used to apply Trim-Away to large cell numbers.
Thus,wesought to develop anoptimized antibody electropora-
tionprotocol. Todetermine themostefficientelectroporationcon-
ditions, we used fluorescently labeled antibodies and quantifiedA and B), membrane-anchoredGFP (C and D), H2B-GFP (E and F), or NLS-GFP
hows minutes (min) from antibody microinjection, 0 min is just before antibody
ith either mRNA for mCherry-TRIM21 or mRNA for mCherry-TRIM21 and anti-
tion. Time shows minutes (min) from start of imaging.
ed line outlines nucleus. Scale bars, 20 mm. Error bars show SD. Number of
pendent experiments.
Figure 3. Trim-Away of Endogenous Eg5 Protein
(A) Schematic of Eg5 Trim-Away and rescue experiments.
(B and C) Oocytes overexpressing TRIM21 and microinjected with either control IgG, anti-Eg5 or treated with monastrol, or oocytes microinjected with anti-Eg5
alone were assessed for spindle morphology. (B) Representative examples and (C) quantification. Microtubules and chromosomes were labeled with mEGFP-
Map4 and H2B-mCherry, respectively.
(D) Whole oocyte lysates were immunoblotted for the indicated proteins.
(E and F) Oocytes overexpressing TRIM21 andmicroinjected with anti-Eg5 antibody were allowed to form amonopolar spindle and thenmicroinjected with either
water or Eg5-mEGFP mRNA and scored for spindle morphology. (E) Representative examples and (F) quantification. Microtubules were labeled with
mCherry-MAP4.
Scale bars, 10 mm. Number of oocytes is specified in brackets. Data from two (D and F) or four (C) independent experiments. P values were calculated with
Fisher’s exact test.
See also Figures S4, S6, and S7 and Movie S2.the number of fluorescent cells upon electroporation (Figures 5A–
5C; STAR Methods). The optimized electroporation protocol re-
sulted in highly efficient delivery of antibody into the cytoplasm
without cell death (Figures 5A–5C and S5A; STAR Methods).
Thismethod of antibody delivery is also compatible with the rapid
observation of phenotypes: live imaging revealed that adherent
cells started to re-adhere within 30 min of electroporation, with
adherence completed by 4 hr (Figures S5B and S5C; Movie S4).
Electroporated cells showed no evidence of stress or damage
and rapidly re-entered the cell cycle with similar division rates
as non-electroporated cells (Figures S5D–S5F; Movie S4).
We also generated stable NIH 3T3 (mouse) and HEK293T (hu-
man) cell lines overexpressing mCherry-TRIM21. These cell lines
proliferated at a similar rate to wild-type cells and behaved indis-tinguishably after multiple passages suggesting that TRIM21
overexpression is stable and nontoxic (Figures S6H–S6J;
STAR Methods). We also analyzed the transcriptome of
TRIM21-overexpressing and wild-type NIH 3T3 cells either with
or without electroporation of a non-targeting antibody, BSA or
PBS. The transcriptomes were closely related under all condi-
tions, with the vast majority of genes being expressed at similar
levels (Figures S6K–S6M; Tables S1, S2, and S3). Notably, tran-
scripts encoding previously described ligands of TRIM21, IRF-3,
IRF-5, Skp2, DAXX, DDX41, and SQSTM1 were not significantly
increased or decreased upon overexpression of TRIM21 (Fig-
ures S6N–S6P). Consistent with this result, neither TRIM21 over-
expression, nor Trim-Away of an endogenous protein caused
changes in the protein level of IRF-3 (Figure S6Q). Together,Cell 172, 1692–1706, December 14, 2017 1697
Figure 4. Trim-Away of Long-Lived Rec8 Protein
(A) Schematic of Rec8 Trim-Away experiment.
(B andC) Eggs overexpressingmEGFP-TRIM21 ormEGFP-TRIM21DPRYSPRY (not shown) weremicroinjected with either control IgG or anti-Rec8 antibody and
chromosome morphology (H2B-mCherry; greys) followed by live imaging. (B) Representative examples and (C) quantification.
(D and E) Single chromatid count (D) and boxplot of time of onset of sister chromatid separation (E) in eggs overexpressing mEGFP-TRIM21 following micro-
injection of anti-Rec8 antibody.
Scale bars, 5 mm. Time shows minutes (min) from microinjection. Number of eggs in brackets. Data from three (C) or two (E) independent experiments. P values
were calculated with Fisher’s exact test.
See also Figures S4, S6, and S7 and Movie S3.these results suggest that cells overexpressing TRIM21 behave
similar to wild-types.
We reasoned that by electroporating antibodies into TRIM21-
overexpressing cell lines it should be possible to target endo-
genous proteins in bulk cell populations for degradation. To
test this, we targeted two proteins that are non-essential for
cell viability: ERK1, a redundant serine/threonine kinase in the
MAPK/ERK signaling cascade (Fre´min et al., 2015), and IKKa, a
catalytic subunit of the IkB kinase (IKK) complex (Hu et al.,
1999; Takeda et al., 1999). Strikingly, both ERK1 and IKKa were
depleted within 1–2 hr of antibody electroporation into TRIM21-
overexpressing cells, with depletion lasting for 3–4 days (Figures
S5G and S5H). The reappearance of ERK1 and IKKa coincided
with the depletion of antibody from the cells (Figure S5H). This
indicates that antibody availability limits the duration of protein
depletion and suggests that the depletion period could be modi-
fied by varying the amount of electroporated antibody.1698 Cell 172, 1692–1706, December 14, 2017We next tested if Trim-Away using antibody electroporation
is compatible with quantitative analysis of cellular phenotypes.
To this end, we targeted the centrosomal protein pericentrin
in NIH 3T3 cells. Strikingly, electroporation of rabbit polyclonal
anti-pericentrin antibody (ab4448) into mCherry-TRIM21-over-
expressing cells led to a complete loss of pericentrin signal at
the centrosome in 95% of cells (Figures 5D and 5E). The high
efficiency of pericentrin loss likely reflects the fact that 95%
of cells receive antibody following electroporation (Figures 5A
and 5C) and 99% of cells overexpress TRIM21 (Figure S6H).
Pericentrin degradation by Trim-Away was confirmed by immu-
noblotting with two different antibodies (Figure 5F). Pericentrin
is proposed to have an important role in the localization of
Cdk5rap2 to the centrosome (Chen et al., 2014; Lee and Rhee,
2011). However, previous studies relied on prolonged, indirect
depletion of pericentrin by RNAi or gene knockout (Chen et al.,
2014; Lee and Rhee, 2011). Thus, it has been impossible to
Figure 5. Trim-Away of Pericentrin by Antibody Electroporation
(A–C) NIH 3T3 andHEK293T cells were electroporated with Alexa Fluor 488-labeled IgG and analyzed 3 hr later by flow cytometry (A and B) or fixed 16 hr later and
analyzed by microscopy (C). At least 2,000 cells were counted for each condition. Percentages correspond to IgG-positive cells falling within the gate drawn.
Scale bars, 10 mm.
(D–H) NIH 3T3 and NIH 3T3-mCherry-TRIM21 cell lines were electroporated with control IgG or anti-pericentrin antibodies and analyzed 16 hr later for pericentrin
(D and E) and Cdk5rap2 localization (G and H). Number of cells in brackets. Scale bars, 5 mm. DNA stained with Hoechst.
(F) Cell lysates were immunoblotted for the indicated proteins. Asterisks show non-specific bands not degraded by Trim-Away.
Data from two independent experiments (E and H). P values were calculated with Fisher’s exact (E) or Student’s t test (H).
See also Figures S4–S7.distinguish between a role for pericentrin in Cdk5rap2 recruit-
ment during the course of the centrosome cycle or in mainte-
nance of Cdk5rap2 at the centrosome. We used Trim-Away to
address this question and investigate howCdk5rap2 localization
is altered upon acute removal of pericentrin. Repeating Trim-
Away and staining for Cdk5rap2 revealed that loss of pericentrinfrom the centrosome leads to a concomitant loss of centrosomal
Cdk5rap2 (Figures 5G and 5H).
To further confirm the specificity of pericentrin degradation,
we repeated Trim-Away with a second mouse monoclonal
anti-pericentrin antibody (BD611815). Pericentrin Trim-Away
with BD611815 also caused pericentrin degradation andCell 172, 1692–1706, December 14, 2017 1699
Figure 6. Selective Trim-Away of Signaling Pathway Components
(A) Schematic of mTOR function. Rapamycin inhibits only mTORC1.
(B) HEK293T and HEK293T-mCherry-TRIM21 cell lines were electroporated with control IgG, anti-mTOR antibody or treated with rapamycin, harvested 5 hr later,
and cell lysates immunoblotted for the indicated proteins.
(C) Schematic of IkBa Trim-Away experiment.
(D and E) HEK293T and HEK293T-mCherry-TRIM21 cell lines transfected with NF-kB-luciferase reporter plasmid were electroporated with PBS, anti-mTOR, or
anti-IkBa antibodies and 5 hr later analyzed for luciferase activity (D) or harvested and lysates blotted for the indicated proteins (E).
Error bars show SD. Representative examples from two (B) or four (D and E) independent experiments. P values were calculated with Student’s t test.
See also Figures S4, S6, and S7.Cdk5rap2 mislocalization (Figures 5F and S5I–S5M). Notably,
pericentrin degradation and Cdk5rap2 mislocalization was
observed just 3 hr post-antibody electroporation (Figures S5I–
S5M), further demonstrating that pericentrin is required to main-
tain Cdk5rap2 at the centrosome. Together, this data shows that
Trim-Away is suitable to rapidly degrade endogenous proteins
and observe cellular phenotypes in bulk cell populations.
Trim-Away Can Rapidly Activate Signal Transduction
Pathways through Selective Degradation
The above experiments show how Trim-Away can be used to
investigate loss-of-function phenotypes. Next, we attempted to1700 Cell 172, 1692–1706, December 14, 2017use Trim-Away to target proteins involved in active signaling
pathways to induce both pathway inactivation and activation.
First, we targeted the protein kinasemTOR as it regulates several
essential cellular functions (Laplante and Sabatini, 2009) (Fig-
ure 6A). Electroporation of anti-mTOR antibody into HEK293T
cells overexpressing mCherry-TRIM21 lead to a reduction in
mTOR protein levels (Figure 6B). Degradation was not complete,
perhaps because a subset of mTOR resides within intracellular
compartments inaccessible to antibody (Betz and Hall, 2013).
Nonetheless, mTOR degradation by Trim-Away was sufficient
to reduce phosphorylation of ribosomal protein 6 at Ser235/
236, consistent with a loss of mTORC1 activity and similar to
Figure 7. Trim-Away in Unmodified Cells and Primary Human Macrophages
(A) The indicated cell lines were electroporated with PBS, anti-IKKa antibody, His-Lipoyl-TRIM21, or anti-IKKa + His-Lipoyl-TRIM21 and whole cell lysates
harvested 3 hr later for immunoblotting.
(B) Schematic of NLRP3 function.
(C) HMDMswere electroporated with PBS, anti-GFP, ant-NLRP3, or anti-IKKa antibodies, then stimulated with 10 ng/mL LPS for 4 hr before collecting whole cell
lysates for immunoblotting.
(legend continued on next page)
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mTORC1 inhibition by rapamycin (Figures 6A and 6B). Impor-
tantly, mTOR also functions in a second complex, mTORC2,
that induces phosphorylation of Akt. However, this activity
cannot be investigated by rapamycin as it is a poor inhibitor of
the mTORC2 complex (Sarbassov et al., 2005) (Figure 6A). In
contrast, mTORC2 function could be efficiently ablated using
Trim-Away. Phosphorylation of Akt at Ser473 was lost upon
mTOR degradation by Trim-Away, but only slightly reduced
upon rapamycin treatment (Figure 6B).
Next, we attempted to use Trim-Away to induce a change
in a transduction pathway that activates rather than inhibits
downstream signaling. We chose the nuclear factor kB (NF-kB)
pathway as this system is constitutively repressed by the inhib-
itor IkBa. Upon stimulation, IKK phosphorylates IkBa leading
to IkBa ubiquitination and degradation, allowing nuclear translo-
cation of the heterodimeric p65 and p50 complex and transcrip-
tion of target genes (Gilmore, 2006). Strikingly, electroporation of
anti-IkBa antibody into HEK293T cells overexpressing mCherry-
TRIM21 triggered both the degradation of IkBa and the substan-
tial induction of NF-kB activity (Figures 6D and 6E). Thus, acute
degradation of IkBa by Trim-Away is sufficient to relieve inhibi-
tion of the NF-kB pathway and trigger downstream signaling.
NF-kB activation following IkBa Trim-Away was not indirectly
due to TRIM21 activation (McEwan et al., 2013), because Trim-
Away of a control endogenous protein, mTOR, triggered only
minor NF-kB activity (Figures 6D and 6E). Electroporation of
anti-IkBa antibody alone triggered a small induction of NF-kB,
although to a much lesser extent than in cells expressing
mCherry-TRIM21 (Figures 6D and 6E). It is possible that this
small induction by anti-IkBa antibody alone was due to minor
disruption of the NF-kB-IkBa interaction, because IkBa protein
was not degraded in this condition (Figure 6E).
Collectively, these data establish that Trim-Away can be used
to perform rapid protein depletion in bulk cell populations upon
electroporation of specific antibodies. Furthermore, Trim-Away
allows specific gain-of-function and loss-of-function pheno-
types to be observed within just a few hours.
Co-electroporation of TRIM21 Protein and Antibody
Facilitate Rapid Protein Degradation in Unmodified
Cell Lines
While Trim-Away performed efficiently when TRIM21 is ectopi-
cally overexpressed, this requires prior modification of a cell
line. We therefore investigated whether TRIM21 could be sup-
plied exogenously in protein form, eliminating the necessity for
prior transfection or transduction. We envisaged that Trim-
Away could be achieved in one step by co-electroporating anti-
body together with recombinant TRIM21 protein. To this end, we
established a protocol to purify functional recombinant TRIM21
(STAR Methods). We tested this method by co-electroporating
recombinant TRIM21 and antibodies against IKKa or ERK1 into
six commonly used cell lines. Remarkably, in all cell lines, this(D) Bonemarrow-derived macrophages (BMDMs) from wild-type (WT) or Trim21 k
antibodies, then stimulated with 10 ng/mL LPS for 4 hr before collecting whole c
(E) HMDMs from 4 different blood donors were electroporated with PBS, anti-GFP
(STAR Methods). Mean IL-1b values taken from 2 replicates for each condition a
See also Figures S4, S6, and S7.
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and S7A). Interestingly, in some cell lines, IKKa and ERK1 were
at least partially degraded when antibody was electroporated
without recombinant TRIM21 (Figures 7A and S7A). This degra-
dation was linked to a marked decrease in the levels of endo-
genous TRIM21, suggesting that the endogenous TRIM21 was
mediating protein degradation.
These data show that Trim-Away can be used to rapidly
degrade endogenous proteins in unmodified cells by simply
electroporating antibody and TRIM21 protein simultaneously. It
also shows that some cell lines have sufficient endogenous
active TRIM21 to mediate protein degradation, although this is
likely to be dependent upon target expression levels.
Trim-Away by Endogenous TRIM21 in Human
Primary Cells
The possibility to directly degrade endogenous proteins by Trim-
Away is potentially transformative for studies of primary human
cells, in which gene editing and RNAi are challenging. We there-
fore tested if we can use Trim-Away to degrade proteins in
normal human lung fibroblasts (NHLFs), primary cells used to
study respiratory infection. Co-electroporation of IKKa or ERK1
antibodies together with recombinant TRIM21 led to efficient
protein degradation in these cells (Figures S7B and S7C). Even
endogenous levels of TRIM21 were sufficient to mediate pro-
tein degradation, as suggested by concomitant degradation of
TRIM21 together with the target protein upon antibody electro-
poration alone (Figures S7B and S7C).
Studying protein function in primary human immune cells has
long represented a difficult challenge (Chow et al., 2011). This is
particularly true for primary macrophages, as their active nucle-
otide sensing machinery makes classical plasmid and siRNA
transfection approaches unfeasible and likely to indirectly induce
stimulation (Hornung and Latz, 2010). Because Trim-Away acts
exclusively at the protein level, this method offers a unique op-
portunity to investigate protein function in primary human mac-
rophages without perturbing them. NLRP3 is an intracellular
signaling molecule expressed in immune cells that triggers the
formation of a multiprotein complex called the inflammasome
in response to diverse pro-inflammatory stimuli. The inflamma-
some directs interleukin-1b (IL-1b) maturation and secretion as
part of a linked inflammatory and cell death response called py-
roptosis (Schroder and Tschopp, 2010). The requirement for the
NLRP3 protein in inflammasome activation has so far only been
shown in mousemacrophages (Sutterwala et al., 2006) and a hu-
man leukemia-derived THP-1 cell line (Papin et al., 2007). We
used Trim-Away to test whether NLRP3 is required for inflamma-
some activation in ex vivo human monocyte-derived macro-
phages (HMDMs). Electroporation of anti-NLRP3 antibody into
HMDMs triggered rapid depletion of NLRP3 (Figure 7C). This
was likely TRIM21-dependent, because NLRP3 was degraded
upon anti-NLRP3 antibody electroporation into macrophagesnockout (T21/) mice were electroporated with PBS, ant-NLRP3, or anti-IKKa
ell lysates for immunoblotting.
, ant-NLRP3, or anti-IKKa antibodies and assayed for inflammasome activation
re shown for each donor. Error bars show SD.
derived from wild-type mice, but not in macrophages from
TRIM21 knockouts (Figure 7D). We did not observe co-degrada-
tion of TRIM21 and anti-NLRP3 antibody (Figures 7C and 7D),
presumably because they were present in large excess to
endogenous NLRP3. Strikingly, Trim-Away of NLRP3 caused a
reduction in IL1-b secretion in response to stimulation with lipo-
polysaccharides (LPS) and the pore-forming toxin Nigericin in
HMDMs from all four blood donors (Figure 7E). Neither electro-
poration of an anti-GFP antibody nor Trim-Away of IKKa had
any effect on IL1-b secretion (Figure 7E). These results demon-
strate for the first time that NLRP3 has a nonredundant and
crucial role in inflammasome activation in primary humanmacro-
phages. Moreover, taken together the above data demonstrate
that Trim-Away is suitable to degrade proteins in a wide range
of cell types, including primary human cells that are intractable
to other methods.
Specificity of Trim-Away Assays
The successful application of Trim-Away to 9 different endoge-
nous proteins in 10 different cell types demonstrates that the
Trim-Away method is widely applicable and cell and substrate
independent. Importantly, Trim-Away did not lead to the degra-
dation of proteins in close spatial proximity of the target proteins:
Trim-Away of IkBa did not cause degradation of NF-kB (Figures
6D and 6E), Trim-Away of individual nucleoporins did not lead to
degradation of the entire nuclear pore complex (Figure S7D),
Trim-Away of pericentrin did not cause degradation of other
centrosomal proteins (Figures 5F and S5M), and Trim-Away
of H2B-GFP did not cause degradation of H2A (Figures S3D–
S3G). However, the fate of multiprotein complexes following
Trim-Away of individual components may depend on the biology
of the complex in question. For example, rapid degradation of
CENP-A using the auxin-inducible degron system also causes
degradation of the CENP-A-interacting protein HJURP (Hoff-
mann et al., 2016). Similarly, degradation of mTOR by Trim-
Away also led to a reduction of Raptor and Rictor, which form
complexes with mTOR (Figures 6A and 6B).
The Trim-Awaymechanism itself is highly specific, as shown in
rescue experiments (Figures 3A, 3E, and 3F) and by using multi-
ple antibodies raisedagainst different regions of the sameprotein
(Figures 5D–5F and S5I–S5M). These approaches can be readily
employed to confirm the specificity of Trim-Away phenotypes.
Non-specific antibodies should be avoided because Trim-Away
with these antibodies can lead to the simultaneous degradation
of several proteins (Figure S7D). Thus, the specificity of the
Trim-Away approach will be determined by the antibody used.
DISCUSSION
Gene knockouts and RNAi are widely used methods to study
protein function. However, both methods act indirectly by block-
ing the expression of a protein and require that the target protein
turns over. This can result in delayed protein disruption, an accu-
mulation of non-specific defects and the activation of compen-
satory mechanisms. Current methods that act directly at the
level of the protein either require that the endogenous protein
is first replaced by a modified protein variant or are only appli-
cable to a very small number of proteins.Here, we have developed a widely applicable technique to
acutely and rapidly degrade endogenous proteins in mammalian
cells without the need for prior modification of the protein-coding
gene or mRNA (Figure 1A). To our knowledge, this is the first
posttranslational protein knockdown approach that can be
readily applied to almost any intracellular protein.
We have shown that Trim-Away can degrade diverse protein
substrates in both mammalian cell culture and primary mouse
and human cells. Importantly, because the TRIM21-antibody
interaction is highly conserved and maintained both within and
between species (Keeble et al., 2008), the Trim-Away approach
should be applicable to any mammalian cell using antibodies
produced in any mammalian species. Trim-Away may also
facilitate loss-of-function experiments in species that are not
genetically tractable such as various marine species, or mam-
mals that have long generation times.
Given that antibodies have been used over decades for
various assays that require native protein recognition such as
immunoprecipitation or immunofluorescence there is a compre-
hensive resource of antibodies with confirmed specificity readily
available for use in Trim-Away assays. The growing pool of re-
combinant nanobodies (Chirichella et al., 2017; Helma et al.,
2015; Pleiner et al., 2015) can also be utilized for Trim-Away sim-
ply by fusion to the Fc domain of conventional antibodies to allow
TRIM21 binding (Figures 2I–2K).
By utilizing specific antibodies, Trim-Away is also suitable
for selectively degrading posttranslationally modified proteins,
splice or mutant protein variants while preserving the unmodi-
fied/wild-type protein; an approach that is not possible using
current DNA- and RNA-targeting methods. Trim-Away could
also be applied to study the function of proteins in selected
cellular compartments. For instance, proteins that function
both in the cytoplasm but also in other membrane-enclosed
compartments or organelles can now be studied selectively in
the cytoplasm without perturbing their function elsewhere,
where they are shielded from antibodies. Vice versa, one could
consider to target antibodies, nanobody-Fc fusions or TRIM21
to specific cellular sites for the local degradation of proteins.
Our observation that the endogenous levels of TRIM21 are suf-
ficiently high for protein degradation in several cell types demon-
strates that Trim-Away may be applicable without introducing
excess TRIM21. This further simplifies the application of Trim-
Away, especially in primary cells. If endogenous TRIM21 levels
are insufficient for protein degradation, antibodies can easily
be co-electroporated with recombinant TRIM21 protein to facil-
itate the complete degradation of target proteins.
In summary, this study provides unprecedented tools for
studying protein function. First, it allows protein function to be
studied in non-dividing primary cells where DNA- and RNA-tar-
geting methods are not suitable. Second, it allows the functional
analysis of long-lived proteins that are resistant to current knock-
down methods that rely on protein turnover. Third, removal of
essential endogenous proteins can now be achieved without
the introduction of protein modifications such as degrons.
Fourth, the remarkable speed of Trim-Away means that pheno-
types can be observed immediately following degradation of
the endogenous protein at any stage of a particular biological
process. Finally, aberrant protein expression or activation is aCell 172, 1692–1706, December 14, 2017 1703
hallmark of many human diseases such as neurodegeneration
(Aguzzi and O’Connor, 2010) and cancer (Hanahan and Wein-
berg, 2011). It may become possible in the future to adapt the
Trim-Awaymethod to develop novel therapeutics that target dis-
ease-causing proteins for degradation.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Strains
Female FVBnmice (8 weeks old) were obtained from a breeding colony that was generated usingmice purchased fromCharles River.
C57BL/6J wild-type (WT) C57BL/6-Trim21tm1Hm/J (T21/) mice were obtained from The Jackson Laboratories. All mice wereCell 172, 1692–1706.e1–e7, December 14, 2017 e3
maintained in a specific pathogen-free environment according to UK Home Office regulations. The experiments involving mice have
been approved by the MRC Cambridge Ethical Review Committee and the UK Home Office under project license numbers PPL 70/
8087 and PPL PCF3F9520.
Cell lines
NIH 3T3, HEK293T, HCT116 andHeLa cells (ATCC) were cultured in DMEMmedium (GIBCO; 31966021) supplementedwith 10%Calf
Serum and penicillin-streptomycin. U2OS cells (ATCC) were cultured in McCoy’s 5A (modified) medium (GIBCO; 36600021) supple-
mented with 10% Calf Serum and penicillin-streptomycin. RPE-1 cells (ATCC) were cultured in DMEM/F-12 medium (GIBCO;
10565018) supplementedwith 10%Calf Serumandpenicillin-streptomycin. Primary normal human lung fibroblast (NHLF) cells (Lonza;
CC-2512)were cultured inFBMmedium (Lonza;CC-3131)with supplements (Lonza;CC4126) according to themanufacturer’s instruc-
tions. All cells were grown at 37C in a 5%CO2 humidified atmosphere and regularly checked to bemycoplasma-free. The sex of NIH
3T3andHCT116cell lines ismale. ThesexofHEK293T,U2OS,RPE-1andHeLacells is female. The sexofNHLFcellswasnotdisclosed
(Lonza; CC-2512). For live imaging, NIH 3T3 cells were plated on 35 mm glass-bottom dishes (MatTek) and culture medium was re-
placed with CO2-independent medium (GIBCO; 18045054) supplemented with 10% Calf Serum, GlutaMAX (GIBCO; 35050061) and
penicillin-streptomycin. Followingelectroporation, cellsweregrown inmediumsupplementedwith10%Calf Serumwithoutantibiotics.
For the proteasome inhibition experiment (Figures 1Dand1E), 25mMMG132 (Sigma;C2211) or a corresponding amount of DMSOwas
added to the medium 90 minutes prior to the experiment. For the mTORC1 inhibition experiments (Figure 6B), cells were treated with
10 nM Rapamycin (CST-9904) or a corresponding amount of DMSO immediately following electroporation.
Primary mouse oocytes
Oocytes were isolated from ovaries of 8-week-old FVBn female mice and cultured in M2 medium covered by mineral oil at 37C.
Isolated oocytes were maintained in prophase arrest by addition of 250 mM dbcAMP (Sigma; D0627). To induce resumption of
meiosis, oocytes were released into dbcAMP-free medium. For the Eg5 inhibition experiments (Figure 3) oocytes were treated
with 100 mM monastrol (Sigma; M8515) or a corresponding amount of DMSO.
Primary human monocyte derived macrophages
Human whole blood samples (ethical approval REC 16/LO/0997) were obtained from the National Health Service Blood and Trans-
plant, Cat no: NC07 (Buffy Coats 50ml). Information about sex, gender, and age of respective donors were blinded. Human Peripheral
Blood Mononuclear cells (PBMCs) were purified from buffy coats by centrifugation over a Ficoll-Paque density gradient (GE Health-
care). CD14+ monocytes were further purified by positive selection using CD14 microbeads (Miltenyi Cat no. 130-050-201). CD14+
monocytes were plated in 6-well dishes with 2 3 106 cells per well and differentiated for 7 days into macrophages in RPMI medium
(GIBCO; 11876093) supplemented with 10% Calf Serum, penicillin-streptomycin and 40 ng/ml recombinant human MCSF (R&D
Systems, 216-MC-025). Macrophages were harvested by incubating cells in ice cold PBS with 2% calf serum and 5 mM EDTA
for 10 minutes at 4C and scraping.
Primary mouse bone marrow derived macrophages
Primary bone marrow derived macrophages (BMDMs) were obtained by culturing bone marrow flushed from the femurs and tibias of
6-8 week old male C57BL/6J wild-type (WT) or C57BL/6-Trim21tm1Hm/J (T21/) mice in DMEM media supplemented with 10% Calf
Serum, penicillin-streptomycin and 40ng/ml recombinant human MCSF (R&D Systems, 216-MC-025). After 6 days of differentiation,
macrophageswereharvestedby incubatingcells in icecoldPBSwith2%calf serumand5mMEDTA for10minutesat4Candscraping.
METHOD DETAILS
Protein expression constructs
The mouse Trim21 coding sequence was cloned from cDNA isolated from C57BL/6 mouse embryonic fibroblasts. The human
TRIM21 coding sequence was cloned from cDNA isolated from HeLa cells. Sequences encoding amino acids 124-462 of mouse
TRIM21 lacking the RING and B Box domains (Trim21DRING-Box) and amino acids 1-281 of mouse TRIM21 lacking the PRYSPRY
domain (Trim21DPRYSPRY) were generated by PCR on the full length Trim21 coding sequence. For transient expression in NIH 3T3
cells, the Trim21, Trim21DRING-Box and Trim21DPRYSPRY coding sequences were inserted into pmEGFP-C1 and pmCherry-C1
vectors (Clontech). For in vitromRNA transcription and expression in oocytes, the Trim21, Trim21DRING-Box and Trim21DPRYSPRY
sequences were inserted with or without N-terminal mEGFP ormCherry (Clontech) into the pGEMHE (Liman et al., 1992) plasmid. For
lentivirus production the mouse Trim21 and human TRIM21 coding sequences were cloned with N-terminal mCherry (clonetech) into
lentiviral vector pSMPP to generate pSMPP-mCherry-Trim21 and pSMPP-mCherry-TRIM21. For recombinant protein production
the human TRIM21 coding sequence was cloned in frame with the His-Lipoyl tag in HLTV vector (Mark Allen) to generate HLTV-
hTRIM21. To generate pGEMHE-mEGFP and pGEHME-mCherry, sequences encoding mEGFP and mCherry were inserted into
pGEMHE. To generate membrane-anchored GFP (pGEMHE-membrane-mEGFP) a sequence encoding the first 15 amino acids of
Gnai2 (MGCTVSAEDKAAAER) containing N-myristol and S-palmitoyl motifs was inserted N-terminal tomEGFP in pGEMHE-mEGFP.
To generate nuclear-localized GFP (pGEMHE-NLS-mEGFP) a sequence encoding the nuclear-localization signal (NLS) frome4 Cell 172, 1692–1706.e1–e7, December 14, 2017
Nucleoplasmin (KRPAATKKAGQAKKKK) was inserted N-terminal to mEGFP in pGEMHE-mEGFP. To generate GFP nanobody fused
to Fc (pGEMHE-vhhGFP4-hIgG1-Fc) the vhhGFP4 nanobody coding sequence (Addgene plasmid #35579) (Caussinus et al., 2011)
was inserted N-terminal to the hIgG1-Fc coding sequence (pFuse-hIgG1-Fc1; Invivogen) into pGEMHE. The previously published
coding sequences were inserted into pGEMHE together with mEGFP or mCherry to generate pGEMHE-H2B-mEGFP (Kanda
et al., 1998), pGEMHE-H2B-mCherry (Kanda et al., 1998), pGEMHE-mCherry-MAP4 (Olson and Olmsted, 1999) and pGEMHE-
mEGFP-EG5 (Kaseda et al., 2012). To generate pGEMHE-mEGFP-Map4, the mouse Map4 coding sequence was amplified from
cDNA isolated from mouse C2C12 cells and inserted with N-terminal mEGFP into pGEMHE. The EGFP-Htt74Q (mutant huntingtin)
and EGFP-Htt23Q (normal huntingtin) constructs were a gift from David Rubinsztein (Addgene plasmids #40261 and #40262) and
described previously (Narain et al., 1999). For in vitro mRNA transcription, pGEMHE plasmids were linearized and capped mRNA
was synthesized with T7 polymerase (Ambion mMessage mMachine T7 kit) according to manufacturer’s instructions.
Transient protein expression
For expression in NIH 3T3 cells, plasmidswere transfected using Fugene 6 (Promega) according tomanufacturer’s instructions 18-24
hours prior to live imaging. For expression in oocytes, in vitro transcribed mRNA was microinjected into prophase-arrested oocytes
as described previously (Schuh and Ellenberg, 2007). For TRIM21 overexpression in oocytes, 6-8 picolitres of Trim21 mRNA was
microinjected at a needle concentration of 0.2 mg/ml. Following mRNA microinjection, oocytes were incubated at 37C for at least
3 hours to allow for protein expression before release from dbcAMP or antibody microinjection. For the Eg5 rescue experiment (Fig-
ure 3), mRNA or a corresponding amount of water was microinjected into oocytes arrested in meiosis I with a monopolar spindle.
Stable cell lines
Lentivirus particles were collected from HEK293T supernatant 3 days after co-transfection of pSMPP-mCherry-Trim21 or pSMPP-
mCherry-TRIM21 constructs with HIV-1 GagPol expressor pcRV1 (a gift from Dr. Stuart Neil) and pMD2G, a gift from Didier Trono
(Addgene plasmid #12259). Transfection was performed with Fugene 6 (Promega). Supernatant was filtered at 0.45 mm before stor-
age at80C. HEK293T and NIH 3T3 cells were transduced with lentivirus particles at multiplicity0.1 transducing units per cell and
selected using puromycin at 2.5 mg/ml from 48 hours post-transduction. Transduced cells expressing high levels of mCherry-TRIM21
exhibited aggregated protein that was non-functional. For NIH 3T3 cells, low expressing cells were therefore selected by flow cytom-
etry (i-Cyt Synergy cell sorter) and a HEK293T single cell clone bearing disperse mCherry-TRIM21 was selected following limiting
dilution. Expression of mCherry-TRIM21 in both cell lines was verified by flow cytometry using cells fixed in 4% formadehyde on
a BD LSR II Flow Cytometer (Beckman Coulter). Flow cytometry data were analyzed using FlowJo software.
Protein Purification
E. coli C41 cells were transformed with HLTV-hTRIM21 plasmid and His-Lipoyl-TRIM21 protein expression induced with 1 mM IPTG
overnight at 18C. Cleared cell lysates were prepared by sonication of cell pellets in 50mMTris pH 8, 150mMNaCl, 1mMDTT, 5mM
Imidazole pH 8, 20% (vol/vol) BugBuster (Novagen) and cOmplete protease inhibitors (Roche), followed by centrifugation 16,0003 g
for 30 min. Lysates were loaded onto Ni-NTA agarose (QIAGEN), and His-Lipoyl-TRIM21 protein eluted with 300 mM Imidazole.
Eluted protein was passed through a HiLoad 26/600 Superdex 200 PG size exclusion column using an A¨KTA pure purification system
(GE Healthcare). Peak fractions were pooled and concentrated using Amicon Ultra-4 centrifugal filter units (Millipore) to a concen-
tration of 6 mg/ml and dialysed in PBS for 2 3 2 hours using Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher). His-Lipoyl-TRIM21
protein aliquots were frozen and stored at 80C.
Antibody microinjection
The anti-GFP antibody used was rabbit anti-GFP (Abcam ab6556). The anti-Eg5 antibody used was rabbit anti-Eg5 (Sigma
HPA010568). The anti-Rec8 antibody used was a gift from Maureen Eijpe (Eijpe et al., 2003). The mouse anti-polyglutamine 3B5H10
antibody was from Sigma (P1874). The control IgG used was normal rabbit IgG (Millipore 12-370). With the exception of anti-Rec8,
all antibodies were concentrated using Amicon Ultra-0.5 100 KDa centrifugal filter devices (Millipore) to remove traces of azide and
replace the buffer with PBS. Prior to microinjection into mouse oocytes, antibodies were diluted in PBS containing 0.05% NP40 to
the following concentrations: anti-GFP (0.73 mg/ml), anti-Eg5 (0.08 mg/ml), control IgG (0.73mg/ml and 0.08 mg/ml), anti-Rec8 (con-
centration unknown), anti-polyglutamine 3B5H10 (5mg/ml). Antibodymicroinjection intomouse oocytes was performed as described
for mRNA microinjection (Schuh and Ellenberg, 2007). Prior to microinjection into NIH 3T3 cells, antibodies were diluted in PBS to
0.5 mg/ml (anti-GFP) or 4.2 mg/ml (3B5H10) and spun at 14,000 rpm for 15 minutes at 4C. Antibody microinjection into NIH 3T3 cells
wasperformedusingaNarishigemicromanipulatorandEppendorfFemtojet systemmountedonaZeissLSM710confocalmicroscope.
Inbrief, pressurewasappliedso that therewasaconstant flowofantibodysolutionoutof theneedle,whichwas then transiently inserted
into the cytoplasm until a slight swelling was observed indicating successful microinjection.
Antibody electroporation
All antibodies used for electroporation were either purchased in azide-free formats or passed through Amicon Ultra-0.5 100 KDa
centrifugal filter devices (Millipore) to remove traces of azide and replace buffer with PBS. All antibodies were diluted to 0.5-1 mg/ml
in PBS prior to electroporation. For some experiments, antibodies were mixed equal volumes with His-Lipoyl-TRIM21 proteinCell 172, 1692–1706.e1–e7, December 14, 2017 e5
(6 mg/ml) or corresponding amounts of PBS and incubated on ice for 30 minutes prior to electroporation. Antibodies used for electro-
poration were Alexa Fluor 488-labeled anti-goat (Molecular Probes A11055), normal rabbit IgG (Millipore 12-370), normal mouse IgG
(Millipore 12-371), Mouse IgG1, kappa monoclonal (MG1-45, abcam, ab18447), rabbit anti-Pericentrin (abcam ab4448), mouse anti-
Pericentrin (30, BD Biosciences 611815), rabbit anti-mTOR (7C10, carrier-free CST-2983BF), rabbit anti-IkBa (E130, abcam
ab215972). rat anti-Nup98 (2H10, abcam ab50610), rabbit anti-ERK1 (Y72, abcam ab214168), rabbit anti-IKKa (Y463, abcam,
ab169743), mouse anti-GFP (9F9.F9, abcam, ab1218) andmouse anti-NLRP3 (Cryo-2, Adipogen, AG-20B-0014). Antibody electropo-
ration was performed using the Neon Transfection System (Thermo Fisher). Cells were washed with PBS and resuspended in Buffer R
(Thermo Fisher) at a concentration of 83 107 cells ml-1. For each electroporation reaction 83 105 cells (10 ml) were mixed with 2 ml of
antibody, antibody/TRIM21orPBS.Themixturewas takenup into a10ml NeonPipetteTip (ThermoFisher) andelectroporatedusing the
followingsettings:1400V, 20ms,2pulses.Electroporatedcellswere transferred tomediumsupplementedwith10%CalfSerumwithout
antibiotics. To determine electroporation efficiency, cells were electroporated with Alexa Fluor-488-labeled IgG (Molecular Probes
A11055) and fixed 3 hours after electroporation in 4% formaldehyde and levels of cell-associated Alexa Fluor 488-labeled IgG were
monitored using a BD FACSCalibur Flow Cytometer (Beckman Coulter). Flow cytometry data were analyzed using FlowJo software.
RNA sequencing
NIH 3T3 and NIH 3T3-mCherry-mTRIM21 cells were resuspended in Buffer R (ThermoFisher) at a concentration of 33 107 cells ml-1.
For each electroporation reaction 33 106 cells (100 ml) were mixed with 7.5 mg of antibody (ab18447), BSA or PBS. The mixture was
taken up into a 100 ml Neon Pipette Tip (Thermo Fisher) and electroporated using the following settings: 1400V, 20ms, 2 pulses. Elec-
troporated cells were transferred to medium supplemented with 10% Calf Serum without antibiotics. 16 h later, cells were washed
with PBS and lysed with Trizol (TRizol reagent, Thermo Fisher, 15596026). For phase separation, chloroformwas added. Total RNA in
the upper layer was precipitated with isopropanol and washed with 70% ethanol. The sample was DNase (Turbo DNase, Thermo
Fisher, 40226) treated, and purified total RNA was phenol/chloroform extracted. The strand specific Illumina TruSeq RNA library
preparation kit v2 with polyA enrichment was used to construct libraries from total RNA. Subsequently the Illumina NextSeq 500 plat-
form and a 75 cycles high output v2 kit were used to sequence the libraries. The produced single-end reads which passed Illumina’s
chastity filter were subject to de-multiplexing and trimming of Illumina adaptor residuals using Illumina’s real time analysis software
(no further refinement or selection). Quality of the reads in fastq format was checked with the software FastQC (version 0.11.5). The
splice aware RNAmapping software STAR (version 2.5.1) was used tomap the reads to the reference genome. To count the uniquely
mapped reads to annotated genes, the software htseq-count (HTSeq version 0.6.0) was used. Normalization of the raw counts and
differential gene expression analysis was carried out with help of the software package DESeq2 (version 1.6.3). Libraries, sequencing
and data analysis described in this section were performed by Microsynth AG (Balgach, Switzerland).
NFkB assay
HEK293T and HEK293T-mCherry-TRIM21 cells were transfected with pGL4.32[luc2P/NF-kB-RE/Hygro] NFkB luciferase reporter
plasmid (Promega E8491) using Fugene 6 (Promega) according to manufacturer’s instructions. After 16-24 hours, cells were electro-
porated with antibodies or PBS and plated in a 96-well plate at a density of 2 3 104 cells per well. Cells were incubated at 37C
for 5 hours before addition of Steadylite Plus luciferase reagent (Perkin Elmer) and analysis on a BMG Pherastar FS plate reader.
Luciferase readout values of 4 replicates for each condition were normalized to the mean value for HEK293T cells electroporated
with PBS to give fold NFkB induction.
Inflammasome assay
Primary human monocyte derived macrophages (HMDMs) were electroporated with antibodies or PBS and plated in a 96-well
plate at a density of 7.5 3 104 cells/well. After 1 hour, cells were stimulated with 10 ng/ml Lipopolysaccharides (LPS; Sigma
L4391) for 2 hours. Cells were then transferred to serum-free medium and stimulated with 10 mM Nigericin (Enzo Life Sciences,
BML-CA421-0005) for a further 2 hours. Cell-free supernatants were harvested, and IL-1b assayed by ELISA (R&D Systems,
DY201) using a BMG Pherastar FS plate reader. Mean IL-1b values were taken from 2 replicates for each condition.
Confocal microscopy
For live imaging, images were acquired with a Zeiss LSM710 microscope equipped with BiG (Binary GaASP) detectors or Zeiss
LSM880 or Zeiss LSM800 microscopes using a 40x C-Apochromat 1.2 NA water-immersion objective and a Zeiss environmental
incubator box, which maintained oocytes and NIH 3T3 cells at 37C without CO2. For fixed cells, images were acquired with a Zeiss
LSM710 microscope or Zeiss LSM780 microscope equipped with a 63x C-Apochromat 1.2 NA oil immersion objective. In some
images, shot noise was decreased with a Gaussian filter.
Immunofluorescence
Cells/oocytes were fixed for 30-60 min at 37C in 100 mM HEPES (pH 7; titrated with KOH), 50 mM EGTA (pH 7; titrated with KOH),
2% formaldehyde (methanol free) and 0.2% Triton X-100. Fixed cells/oocytes were incubated in PBS with 0.1% Triton X-100
overnight at 4C. Antibody incubations were performed in PBS, 3%BSA and 0.1% Triton X-100. Primary antibodies usedwere rabbit
anti-Pericentrin (abcam ab4448; 1:200), rabbit anti-Cdk5rap2 (Millipore ABE236; 1:200), mouse anti-g-tubulin (GTU88, Sigma T6557;e6 Cell 172, 1692–1706.e1–e7, December 14, 2017
1:1000) and rabbit anti-Histone H2A (abcam ab18255; 1:200). Secondary antibodies used were Alexa Fluor 488-labeled anti-rabbit
(Molecular Probes A11034; 1:400), Alexa Fluor 647-labeled anti-rabbit (Molecular Probes A21245; 1:400) and Alexa Fluor 647-labeled
anti-mouse (Molecular Probes A21236; 1:400). DNA was stained with 5 mg ml-1 Hoechst 33342 (Molecular Probes H3570).
Immunoblotting
Oocytes were washed in PBS, resuspended in NuPAGE LDS Sample Buffer (Thermo Fisher) and heated at 95C for 5 mins. Cell lines
and primary macrophages were washed in PBS, lysed in RIPA buffer (CST-9806) supplemented with a protease inhibitor cocktail
(Roche), spun at 14000G for 10min and cleared lysates mixed with NuPAGE LDS Sample Buffer and heated at 95C for 5 mins. Sam-
ples were run on NuPAGE 4%–12% Bis-Tris gels (Thermo Fisher) and transferred onto nitrocellulose membrane. Antibody incuba-
tions were performed in PBSwith 5%milk and 0.1% Tween-20. Primary antibodies usedweremouse anti-Eg5 (10C7, Novus NB100-
78467, 1:500), rabbit anti-Eg5 (HPA010568; 1:500), rabbit anti-mCherry (Abcam ab167453; 1:10000), mouse anti-Pericentrin (30, BD
Biosciences 611815; 1:1000), rabbit anti-Pericentrin (abcamab4448; 1:2000), rabbit anti-Cdk5rap2 (Millipore ABE236; 1:500),mouse
anti-g-tubulin (GTU88, Sigma T6557; 1:2000), rabbit anti-PCM1 (Sigma HPA023374; 1:500), rabbit anti-mTOR (7C10, CST-2983;
1:1000), rabbit anti-Raptor (Millipore 09-217; 1:1000), rabbit anti-S6 ribosomal protein (5G10, CST-2217; 1:000), rabbit anti-phos-
pho-S6 ribosomal protein ser235/236 (D57.2.2E, CST4858; 1:2000), rabbit anti-Rictor (53A2, CST-2114, 1:1000), rabbit anti-Akt
(C67E7, CST-4691, 1:1000), rabbit anti-phospho-Akt ser473 (D9E, CST-4060), mouse anti-IkBa (L35A5, CST-4814; 1:1000), rabbit
anti-IkBa (E130, abcam ab215972; 1:5000), rabbit anti-NFkB p65 (D14E12, CST-8242, 1:1000), rabbit anti-ERK1 (Y72, abcam
ab214168; 1:10000), rabbit anti-IKKa (Y463, abcam ab169743; 1:5000), mouse anti-NLRP3 (Cryo-2, Adipogen AG-20B-0014;
1:500), rabbit anti-ASC (AL177, Adipogen AG-25B-000; 1:500), mouse anti-TRIM21 (D-12, Santa Cruz Biotechnology sc-25351;
1:500), rabbit anti-IRF-3 (Millipore 07-2193; 1:1000), rat anti-Nup98 (2H10, abcam ab50610; 1:1000), mouse anti-Nuclear Pore Com-
plex Proteins (Mab414; abcam ab24609; 1:1000); rabbit anti-Nup62 (abcam ab96134; 1:1000), mouse anti-b-actin HRP-conjugated
(Santa Cruz sc-47778 HRP; 1:1000) rat anti-tyrosinated-a-tubulin (YOL1/34, AbD Serotec MCA78G; 1:5000) and rabbit anti-COXIV
(LI-COR 926-42214; 1:5000). HRP-coupled secondary anti-mouse (Dako P0260), anti-rabbit light chain specific (Millipore AP200P),
anti-rabbit (Fisher 31462), anti-rabbit light chain specific (Millipore MAB201P) and anti-rat (Santa Cruz sc-2032) were detected by
enhanced chemiluminescence (Amersham, GE Healthcare) and X-ray films.
QUANTIFICATION AND STATISTICAL ANALYSES
Measurement of GFP fluorescence
Three-dimensional time-lapse images were acquired using Zeiss’s MultiTime Series macro. For NIH 3T3 cells, 7 confocal z sections
every 1.0 mm covering the entire cell were captured just before antibody microinjection and in 5 minute intervals from microinjection
onward. For oocytes, 3 confocal z sections every 1.3 mm surrounding either the center of the cell (for free GFP and membrane-
anchored GFP) or the maximum fluorescence (for H2B-GFP and nuclear-localized GFP) were captured just before antibody micro-
injection and in 2 minute intervals frommicroinjection onward. Using ImageJ software, the integrated density (the product of the area
and mean intensity) was measured for the entire cell/oocyte from a single z section at each time point. GFP fluorescence was calcu-
lated by subtracting the product of the mean intensity of the background (a region outside the cell/oocyte) and the area of the cell/
oocyte from the integrated density. GFP fluorescence values were normalized to the time point prior to antibody microinjection. For
half-life measurements, Prism (GraphPad) software was used to fit single phase decay curves to the mean values of GFP fluores-
cence starting after the initial lag phase.
Immunofluorescence quantification
To quantify centrosomal Cdk5rap2, cells stained for Cdk5rap2 and g-Tubulin were imaged (19 z-confocal sections every 0.5 mm).
Centrosomes were segmented by applying a threshold in the g-Tubulin channel using the isosurface function of Imaris (Bitplane) to
generate a 3.5 mmdiameter 3D centrosome region. Themean intensity for Cdk5rap2 within the centrosome region wasmeasured us-
ing Imaris (Bitplane) and exported into Microsoft Excel. To quantify chromosomal H2B-GFP and H2A, oocytes expressing H2B-GFP
and stained for histone H2A and DNA were imaged (single confocal section through the center of the chromosomes). Chromosomes
were segmented by applying a threshold in the DNA channel using the isosurface function of Imaris (Bitplane). The mean intensity for
H2B-GFP and H2A within the chromosome region was measured using Imaris (Bitplane) and exported into Microsoft Excel.
Statistical Analysis
Average (mean), standard deviation (s.d.) and statistical significance based on Student’s t test (two-tailed) for absolute values or
Fisher’s exact test (two-tailed) for category values were calculated in Microsoft Excel or Graphpad Prism. All boxplots show median
(line), mean (small square), 1st, 99th (crosses), 5th, 95th (whiskers) and 25th and 75th percentiles (boxes).
DATA AND SOFTWARE AVAILABILITY
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Supplemental Figures
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Figure S1. Trim-Away of GFP in NIH 3T3 Cells, Related to Figure 1
NIH 3T3 cells expressing free GFP (green) and either mCherry-TRIM21 (A-D), mCherry (E and F) or mCherry-TRIM21DRING-Box (G and H) (magenta) were
microinjected with either anti-GFP antibody (A, B and E-H) or control IgG (C and D). Time shows minutes (min) from antibody microinjection; 0 min is just before
antibodymicroinjection. Scale bars, 10 mm.Graphs showplots for individual cells (gray) andmean value (black). Data from three independent experiments (B, D, F
and H).
See also Movie S1.
(legend on next page)
Figure S2. Trim-Away of GFP in Mouse Oocytes, Related to Figure 2
(A–H) Oocytes expressing free GFP (green) and either mCherry-TRIM21 (A-D), mCherry (E and F) or mCherry-TRIM21DRING-Box (G and H) (magenta) were
microinjected with either anti-GFP antibody (A, B and E-H) or control IgG (C and D). Time shows minutes (min) from antibody microinjection, 0 min is just before
antibody microinjection. Scale bars, 20 mm. Graphs show plots for individual oocytes (gray) and mean value (black). Data from two independent experiments
(B, D, F and H).
(I) Oocytes expressing either mCherry-TRIM21 and free GFP, or mCherry-TRIM21 alone were microinjected with control IgG or anti-GFP antibodies and whole
cell lysates harvested 1 hour later for immunoblotting.
(J and K) Oocytes were microinjected with varying amounts of gfp ormCherry-Trim21mRNA, incubated for 3-5 hours to allow GFP and mCherry-TRIM21 protein
expression, microinjected with either PBS, control IgG or ant-GFP antibodies and GFP fluorescence determined 2 hours later by microscopy. Number of oocytes
specified in brackets. P values were calculated with Student’s t test.
Figure S3. Trim-Away of Diverse Cellular Substrates, Related to Figures 1 and 2
(A) Prism (GraphPad) software was used to fit single phase decay curves to the mean values (black crosses) of GFP fluorescence taken from data shown in
Figures 1C, 2B, 2D, 2F, and 2H. T1/2 indicates half-life in minutes (min). R2 indicates goodness of fit of single phase decay curve.
(B and C) Oocytes overexpressing mCherry-TRIM21 (not shown) and H2B-GFP (greys) were arrested in prophase or metaphase of meiosis II and microinjected
with anti-GFP antibody. Time shows minutes (min) from antibody microinjection. White dashed lines outline oocytes. Yellow arrows show H2B-GFP. Yellow
dashed lines outline nucleus. Scale bars, 20 mm. Error bars show s.d. Number of oocytes in brackets. Data from two independent experiments.
(D) Oocytes overexpressing mCherry-TRIM21 (magenta) and H2B-GFP (green) were microinjected with anti-GFP antibody. mCherry-TRIM21 recruitment and
H2B-GFP degradation occurs in the chromosome region, suggesting that H2B-GFP is degraded while assembled in nucleosomes. Time minutes (min) from
microinjection. Scale bar, 20 mm.
(E) Oocytes overexpressing mCherry-TRIM21 and H2B-GFP were microinjected with either control IgG or anti-GFP antibody and fixed 1 hour later for immu-
nofluorescence. DNA stained with Hoechst. Scale bar, 5 mm.
(D–G) Trim-Away of H2B-GFP does not cause degradation of H2A. Immunofluorescence images show normal chromosome morphology and H2A localization
following H2B-GFP degradation (E). Boxplots of H2B-GFP (F) and H2A (G) intensity in the chromosome region. Degradation of H2B-GFP did not affect the levels
of histone H2A on chromosomes, implying that the remaining components of the histone complex were not co-degraded with H2B-GFP. Number of cells in
brackets. Data from two independent experiments. P values were calculated with Student’s t test.
Figure S4. Selective Trim-Away of Mutant Huntingtin Protein, Related to Figures 1–7
(A and B) NIH 3T3 cells overexpressing mCherry-TRIM21 (not shown) and either EGFP-Htt74Q (mutant Huntingtin; greys) or EGFP-Htt23Q (normal huntingtin;
greys) were microinjected with 3B5H10 antibody. Time shows minutes (min) from antibody microinjection; 0 min is just before antibody microinjection. Dashed
line outlines cell. Scale bars, 10 mm.
(C and D) Oocytes co-expressing TRIM21, EGFP-Htt74Q (mutant Huntingtin; magenta) and EGFP-Htt23Q (normal huntingtin; green) were imaged before and
2.5 hours after microinjection of 3B5H10 antibody. Scale bars, 20 mm.
Error bars show s.d. Number of cells in brackets in (B); n refers to number of oocytes in (D). Data from two independent experiments.P values were calculated with
Student’s t test.
(legend on next page)
Figure S5. Time Frame for Protein Depletion by Trim-Away, Related to Figure 5
(A–F) NIH 3T3-mCherry-TRIM21 cells were taken up into the Neon Pipette Tip and either electroporated or not (mock). Percentage of dead cells was determined
using the trypan blue exclusion assay (A). For long-term analysis of cellular behavior cells were imaged every 15 min for 70 h following electroporation (B-F). For
the growth curves cell density was normalized to the initial density once cells had adhered (D). For adherence analysis the percentage of spread cells was
quantified in each frame (B and C). Doubling times (E and F) were calculated taking the 5 h time point as reference, because cells were fully adhered then. Data
from three independent experiments. Error bars show s.d. P values were calculated with Student’s t test. See also Movie S4.
(G and H) HEK293T-mCherry-TRIM21 cells were electroporated with either control IgG, anti-ERK1 or anti-IKKa antibodies and whole cell lysates harvested at the
indicated times after electroporation for immunoblotting.
(I–M) NIH 3T3-mCherry-TRIM21 cells were electroporated with control IgG or anti-Pericentrin antibody (BD611815) and 3 hours later analyzed for Pericentrin
(I and K) or Cdk5rap2 (J and L) localization or cell lysates were immunoblotted for the indicated proteins (M). Merge also shows DNA stained with Hoechst.
Number of cells in brackets. Scale bars, 5 mm. Data from two independent experiments. P values were calculated with Fisher’s exact (K) or Student’s t test (L).
Figure S6. TRIM21 Overexpression Does Not Perturb Cells, Related to Figures 1–7
(A) Oocytes microinjected with either water (control) or Trim21 mRNA (TRIM21 OE) were imaged for sixteen hours following release from prophase arrest. Mi-
crotubules and chromosomes were labeled with mEGFP-Map4 and H2B-mCherry respectively. Time shows hours and minutes (h:min) from nuclear envelope
breakdown (NEBD). Scale bars, 10 mm. White dashed line outlines oocyte. Yellow dashed line outlines nucleus.
(legend continued on next page)
(B–G) Key events in meiosis were quantified. Number of oocytes is specified in brackets. P values were calculated with Fisher’s exact test (B, D, E and G) or
Student’s t test (C and F).
(H and I) NIH 3T3, NIH 3T3-mCherry-mTRIM21, HEK293T and HEK293T-mCherry-hTRIM21 cell lines were analyzed by flow cytometry. At least 2000 cells were
counted for each condition. Percentages correspond to mCherry-positive cells falling within the gate drawn.
(J) NIH 3T3 and NIH 3T3-mCherry-mTRIM21 cells (NIH 3T3 mix) or HEK293T and HEK293T-mCherry-hTRIM21 cells (HEK293T mix) were mixed 50:50 and
percentage mCherry cells analyzed by flow cytometry every 24h for 7 days. At least 10,000 cells counted at each time point. Error bars show s.d. Data from 3
independent replicates.
(K–M) Transcriptomes of NIH 3T3-mCherry-mTRIM21 cells were compared to wild-type NIH 3T3 cells by RNA-seq analysis (STAR Methods) following elec-
troporation with PBS (K), BSA (L) or IgG (M). A total of only 8 protein-encoding transcripts were consistently downregulated more than 2-fold in the NIH 3T3-
mCherry-mTRIM21 cells (Kdm5d, Ddx3y, Eif2s3y, Uty, Asb4, Fat4, Papss2 and Lama2), although we cannot rule out the possibility that this is an indirect
consequence of lentivirus construct integration rather than a direct consequence of TRIM21 overexpression.
(N–P) Relative expression levels of genes encoding proteins reported to be ligands of TRIM21. Taken from RNA sequencing data. Irf8 was not detected.
See also Tables S1, S2, and S3.
(Q) HEK293T and HEK293T-mCherry-hTRIM21 cells were electroporated with PBS or anti-IKKa antibody and whole cell lysates harvested 3 hours later for
immunoblotting. IRF-3 protein levels are unaffected by TRIM21 overexpression or activation.
Figure S7. Requirements for Trim-Away Efficiency and Specificity, Related to Figures 1–7
(A) The indicated cell lines were electroporated with PBS, anti-ERK1 antibody, His-Lipoyl-TRIM21, or anti-ERK1 + His-Lipoyl-TRIM21 and whole cell lysates
harvested 3 hours later for immunoblotting.
(B and C) Normal human lung fibroblasts (NHLFs) were electroporated with the indicated proteins/antibodies and whole cell lysates harvested 3 hours later for
immunoblotting.
(D) HEK293T andHEK293T-mCherry-TRIM21 cell lines were electroporatedwith control IgG or an antibody directed against the Nucleoporin Nup98 (anti-Nup98),
harvested 3 hours later and lysates immunoblotted for the indicated proteins. The Nup98 antibody was raised against the Nup98 N terminus, which is rich in
phenylalanine-glycine (FG) repeats. The FG-repeats are shared by several other nucleoporins collectively known as the FGNups (Brohawn et al., 2009). Asterisks
show additional bands recognized by the anti-Nup98 antibody which are the same size as Nup214 and Nup62 recognized by the Mab414 and anti-Nup62
antibodies respectively. Consistent with non-specific binding, Trim-Away using the anti-Nup98 N-terminal antibody also triggered degradation of Nup62 and
Nup214. Other nucleoporins Nup358 and Nup153 were not degraded, suggesting that co-depletion was not the result of degradation of the entire nuclear pore
complex.
